

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		Application Number	10/626,681
		Filing Date	July 24, 2003
		First Name Inventor	Alanine
		Group Art Unit	
		Examiner Name	
Sheet 1 of 1	Attorney Docket Number	21237	

### U.S. PATENT DOCUMENTS


Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
<i>u</i>	A2	2002/019383		Achard, et al.	02-14-2002
<i>u</i>	A3	2001/034344		Mittendorf, et al.	10-25-2001
<i>u</i>	A4	6,432,984		Barth, et al.	08-13-2002

### FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>4</sup>
		Office <sup>3</sup>	Number <sup>3</sup>	Kind Code <sup>2</sup> (if known)			
<i>u</i>	B15	WO 92	18490		Hoffmann-La Roche	10-29-1992	
	B16	FR 2	789 078		Sanofi SA	08-04-2000	✓
	B17	WO 01	28557		University of Connecticut	04-26-2001	
	B18	WO 01	29007		University of Connecticut	04-26-2001	
	B19	WO 02	36590		Amrad Operations Pty Ltd.	05-10-2002	
<i>u</i>	B20	WO 02	42248		Novartis AG	05-30-2002	
Examiner Signature	<i>u</i>	Date Considered			11/23/04		

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

[illegible]

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

137202



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

## Complete if Known

Application Number	10/626,681
Filing Date	July 24, 2003
First Name Inventor	Alanine
Group Art Unit	
Examiner Name	
Attorney Docket Number	21237

Sheet 1 of 2

## U.S. PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
<i>u</i>	A1	5,624,941		Barth, et. al.	04-29-1997


## FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>4</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
<i>u</i>	B1		EP658546		SANOI- SYNTHELABO	06-21-1995	
	B2		EP656354		SANOI	06-07-1995	
	B3		EP576357		SANOI	06-07-1995	
	B4		EP 0216831		BIGADAN A/S, HOJBOGARD BIOGASTEKNOLOGI	08-04-1987	
	B5		WO0224630		ELI LILLY & CO.	03-28-2002	
	B6		WO0015609		MIGNANI	03-23-2000	
	B7		WO0164634		AVENTIS PHARMA S.A.	09-07-2001	
	B8		WO0228346		AVENTIS PHARMA S.A.	04-11-2002	
	B9		WO0164632		AVENTIS PHARMA S.A.	09-07-2001	
	B10		WO0164633		AVENTIS PHARMA S.A.	09-07-2001	
	B11		WO0132663		SANOI- SYNTHELABO	05-10-2001	
	B12		WO0046209		SANOI- SYNTHELABO	08-10-2000	
	B13		WO9719063		SANOI	05-29-1997	
<i>u</i>	B14		WO0158869		BRISTOL-MYERS SQUIBB CO.	08-16-2001	

Examiner Signature	<i>Cheng</i>	Date Considered	11/23/04
-----------------------	--------------	-----------------	----------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO		Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		Application Number	10/626,681	
		Filing Date	July 24, 2003	
		First Name Inventor	Alanine	
		Group Art Unit		
		Examiner Name		
Sheet	2	2	Attorney Docket Number	21237

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
W	C1	D. Shire, et. al, J. Biol. Chem. 270 (8) (1995) 3726-31	
	C2	S. Munro, et. al. Nature 365 (1993) 61-61	
	C3	Y. Gaoni, et. al. J. Am. Chem. Soc, 86 (1964) 16	
	C4	R. Mechoulam (Ed.) in "Cannabinoids as therapeutic Agents", (1986), pp. 1-20, CRC Pr	
	C5	E.M. Williamson, F. J. Evans, Drugs 60 (6) (2000) 1303-1314	
	C6	R. G. Pertwee, Curr. Med. Chem., 6 (8) (1999) 635-664	
	C7	W.A. Devane, et. al. Science 258 (1992) 1946-9	
	C8	V. Di Marzo, et. al., Trends in Neuroscience 21 (12) (1998) 521-8	
	C9	A.C. Porter, C.C. Felder, Pharmacol. Ther., 90 (1) (2001) 45-60	
	C10	C.M. Williams, T.C. Kirkham, Psychopharmacology 143 (3) (1999) 315-317	
	C11	C.C. Felder, et. al., Proc. Natl. Acad. Sci. USA 90 (16) (1993) 7656-7660	
	C12	G. Colombo, et. al., Life Sci. 63 (8) (1998) L113-PL117	
	C13	V. Di Marzo, et. al., Nature 410 (6830) 822-825	
	C14	F. Barth, et. al. "Cannabinoid antagonists: From research tools to potential new drugs", Abstracts of Papers, 222 <sup>nd</sup> ACS National Meeting, Chicago, IL, United States, August 26-30, 2001	
	C15	AAI; M. Pacheco, et. al. Exp. Ther. 257 (1) (1991) 170-183	
	C16	F.M. Casiano, et. al. NIDA Res. Monogr. 105 (1991) 295-6	
	C17	AM630, K. Hosohata, et. al. Life. Sci 61 (1997) 115-118	
	C18	R. Pertwee, et. al., Life Sci. 56 (23-24) (1995) 1949-55	
	C19	LY320135, C.C. Felder, et. al., J. Pharmacol. Exp. Ther. 284, (1) (1998) 291-297 disclosed in WO9602248	
	C20	M. Kanyonyo, et. al., Bioorg. Med. Chem. Lett. 9 (15) (1999) 2233-2236	
W	C21	F. Ooms, et. al., J. Med. Chem. 45 (9) (2002) 1748-1756	
Examiner Signature	cbx		DATE CONSIDERED
			11/23/04

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup>Unique citation designation number. <sup>3</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

133204